Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Aevi Genomic Medicine Inc. (GNMX)

0.216   0.012 (5.62%) 01-18 15:59
Open: 0.2045 Pre. Close: 0.2045
High: 0.22 Low: 0.195
Volume: 2,888,660 Market Cap: 14M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.22 - 0.221 0.221 - 0.222
Low: 0.188 - 0.189 0.189 - 0.19
Close: 0.218 - 0.22 0.22 - 0.221

Technical analysis

as of: 2019-01-18 4:32:22 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. This stock is ready for a new bullish move. It is relatively safe to buy now, a new upward move is expected.
Target: Six months: 0.96     One year: 1.44
Support: Support1: 0.17    Support2: 0.14
Resistance: Resistance1: 0.83    Resistance2: 1.23
Pivot: 0.31
Moving Average: MA(5): 0.20     MA(20): 0.46
MA(100): 1.04     MA(250): 1.35
MACD: MACD(12,26): -0.22     Signal(9): -0.22
Stochastic oscillator: %K(14,3): 3.44     %D(3): 3.05
RSI: RSI(14): 24.70
52-week: High: 2.65  Low: 0.17  Change(%): -85.8
Average Vol(K): 3-Month: 139536  10-Days: 469358

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
GNMX has closed above bottom band by 38.1%. Bollinger Bands are 105.4% wider than normal. The large width of the bands suggest high volatility as compared to GNMX's normal range. The bands have been in this wide range for 16 bars. This is a sign that the current trend might continue.

Headline News

2019-01-02T16:46:01-05:00
Aevi Genomic's AEVI-001 flunks mid-stage ADHD study

2019-01-02T16:30:00-05:00
Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
atoplab.com
Tweet this page Share on Google+ Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 64.77
Shares Float (M) 57.59
% Held by Insiders
% Held by Institutions 21.50
Shares Short (K)
Shares Short P. Month (K)

Stock Financials

EPS
EPS Est. Current Year -0.850
EPS Est. Next Year -0.750
EPS Est. Next Quarter -0.160
Forward EPS -0.660
Book Value (p.s.) 1.070
PEG Ratio
Profit Margin
Operating Margin
Return on Assets (ttm) -169.4
Return on Equity (ttm) -263.8
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M) -27.46
Levered Free Cash Flow (M) -16.61

Stock Valuations

P/E
P/E Growth Ratio
P/BV 0.20
P/S
P/CF -0.51

Dividends & Splits

Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.